Alphagan : Patient Resources

Patient resources

The following links are recommended resources with additional information about glaucoma:

Children's Glaucoma Foundation

The Glaucoma Foundation (TGF)

Glaucoma Research Foundation (GRF)

GRF GLEAMS Newsletter

Glaucoma Service Foundation to Prevent Blindness at Wills Eye Hospital

International Glaucoma Association

New York Glaucoma Research Institute

Please be aware that by selecting any link above, you are leaving the
ALPHAGAN^® P Web site. Links to all external sites are provided as a resource to our visitors. Allergan accepts no responsibility for the content of these sites. Allergan does not control these sites, and the opinions, claims, or comments expressed on these sites should not be attributed to Allergan.

ALPHAGAN^® P ophthalmic solution is approved for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Important Safety Information
ALPHAGAN^® P (brimonidine tartrate ophthalmic solution) 0.1% should not be used in patients receiving monoamine oxidase (MAO) inhibitor therapy. Adverse events occurring in approximately 10% to 20% of the subjects included: allergic conjunctivitis, ocular redness, and itching. Adverse events occurring in approximately 5% to 9% included: burning sensation, increased ocular lymph nodules, increased ocular pressure, ocular allergic reaction, dry mouth, and blurred vision.

Please click here for full Prescribing Information.